British Journal of Dermatology
British Journal of Dermatology
5 years ago

Phase IV head-to-head randomised controlled trial comparing ingenol mebutate 0.015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp

T. Larsson, M.L. Østerdal, C. Serra Guillén, T. Skov, C.A. Harwood, E. Stockfleth
Background Ingenol mebutate (IngMeb) and diclofenac sodium (DS) are approved treatments for actinic keratosis (AK). Objectives Compare efficacy and safety of IngMeb 0.015% gel with DS 3% gel. Methods Patients with 4–8 visible, discrete AK lesions on face/scalp in a 25 cm2 contiguous area of skin were randomised 1:1 to IngMeb once-daily for 3 consecutive days, or DS twice-daily for 90 days, following label instruction. Patients presenting with AK lesions at Week 8 following IngMeb were offered a second IngMeb course. The primary endpoint was complete clearance of AK lesions (AKCLEAR 100) at end of first treatment course (Week 8, IngMeb; Week 17, DS). Secondary endpoints included AKCLEAR 100 at end of last treatment course and Week 17; adverse events (AEs) were assessed at these time points. Patients completed Treatment Satisfaction Questionnaires for Medication (TSQM; Week 17). Results AKCLEAR 100 at end of first treatment course was higher with IngMeb (34.5%) versus DS (23.5%; p=0.006). AKCLEAR 100 at end of last IngMeb course (53.3%) and Week 17 (45.1%) was higher than DS (both p<0.001). The most frequent AE was application-site erythema (IngMeb 19%; DS 12%). Treatment-related AE (TRAE) duration was shorter with IngMeb. TRAE withdrawals were lower for IngMeb (2%) versus DS (6%). TSQM scores for global satisfaction (p<0.001) and effectiveness (p=0.002) were higher with IngMeb, as was dosing instruction adherence (≥90% versus 70%). Conclusion AKCLEAR 100, patient treatment satisfaction and effectiveness were significantly higher with IngMeb versus DS, demonstrating superiority of IngMeb for AK treatment on face/scalp (NCT02406014). This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/bjd.16048

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.